Last checked at 12 Apr 2017 07:15
Hardman Research: Another important box ticked
Another important box ticked: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. In two years, management has hit several key milestones, moving Affimers from being an 'interesting concept' to one of 'real opportunity' and de-risking the technology as the next platform of biopharmaceutical drugs.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/12.04.17-another-important-box-ticked.pdf
To contact us: Hardman & Co 11/12 Tokenhouse Yard London EC2R 7AS | Contacts: Dr Martin Hall mh@hardmanandco.com Dr Dorothea Hill dmh@hardmanandco.com Dr Gregoire Pave gp@hardmanabdco.com Telephone: +44 20 7929 3399 Follow us on Twitter @HardmanandCo |
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.